HOME >> MEDICINE >> NEWS
Fever of unknown origin: a marker for occult cancer?

EMBARGO: 00:01H (London time) Wednesday September 28, 2005. In North America the embargo lifts at 6:30pm ET Tuesday September 27, 2005. FEVER OF UNKNOWN ORIGIN: A MARKER FOR OCCULT CANCER? Fever of unknown origin might be a marker of occult cancer, according to research published online today by THE LANCET ONCOLOGY.

Fever of unknown origin is characterised by a fever of more than 3 weeks duration, temperatures of more than 38.3C and a failure to identify the origin of the fever. Underlying causes of these fevers are difficult to diagnose, but proposed causes are infections, cancers and collagen-vascular diseases. Henrik Toft Sorensen and colleagues hypothesised that patients with fever of unknown origin might have a higher risk of cancer than the general population.

To test their theory, they assessed 43 205 patients discharged for the first time from Danish hospitals after treatment for fever of unknown origin from 1977-98. Using registry data, they examined whether these patients had a higher risk of subsequent cancer than that expected based on cancer incidence in the general population. They also compared survival of these patients with cancer patients without fever, but matched for cancer site, age at diagnosis of cancer and year of cancer diagnosis.

Within the first year of follow-up after discharge from hospital, patients with fever had an increased risk of developing cancer and 399 cancers were diagnosed (standardised incidence ratio 2.3 [95%CI 2.1-2.5]). This risk was highest for haematological cancers and sarcomas and, although reduced, the overall increased risk remained after 1 year of follow-up. Some cancer patients with fever also had a worse prognosis than did the controls without fever (mortality ratio 1.4 [1.2-1.6]).

Prof Sorensen states "Heightened diagnostic effort could account for some of the association; however, after several years of follow-up, diagnostic bias should not be a major contributing
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
+1-212-633-3810
Lancet
27-Sep-2005


Page: 1 2

Related medicine news :

1. Yellow Fever
2. Benefits of testosterone treatment unknown, research shows
3. The unknown risks of arthritis
4. Daycare illness guidelines exist, but largely unknown
5. Depression linked to previously unknown dopamine regulator
6. Novel candidate biomarker for heart failure also strongly predicts risk of death
7. USC researchers show that molecular markers predict tumor recurrence
8. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
9. Advances in screening and markers improve early detection of colorectal cancer
10. Genetic marker linked to aggressive prostate cancer
11. Genetic markers in surrounding tissues linked to breast cancer tumor grade, presence of metastases

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/18/2017)... ... February 17, 2017 , ... ... Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 — ... looking to reduce their regulatory burden? Pay dividends in enhanced and predictable ...
(Date:2/18/2017)... California (PRWEB) , ... February 17, 2017 , ... ... info@drvallecillos.com , drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn ... fat cells. , Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around ...
(Date:2/18/2017)... ... February 18, 2017 , ... A new directory from the ... to easily connect elderly veterans of America's armed forces to a range of ... conveys material on this year's increase in the Veterans Pension with Aid & ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare ... designed to further positively impact the health and wellness of our community in ... it our duty to seriously consider releasing our assets beyond our 5% targeted ...
(Date:2/17/2017)... , ... February 17, 2017 ... ... Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 — 1:30 ... the critical reimbursement questions manufacturers should be asking before selecting an FDA ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, ... is expected to grow at a CAGR of 9.4% from 2017-2022 ... grow at a CAGR of 9.5% from 2017 to 2027. The ... ... will benefit you Read on to discover how you can ...
(Date:2/17/2017)... , Feb. 17, 2017 Arvinas LLC, ... drugs based on protein degradation, today announced the presentation ... (AR) PROTAC during a poster session at the American ... GU) in Orlando, FL. ... validate our platform and the potential of PROTACs to ...
(Date:2/17/2017)... , Feb 17, 2017 Research and Markets has ... Business Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , and Rest of World. Annual ... a six-year historic analysis is provided for these markets. Market data and ...
Breaking Medicine Technology:
Cached News: